NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Group 1 - NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) has a strong late-stage cardiovascular pipeline in the biotech sector, which remains relatively unnoticed in the market [1] - The current market focus is primarily on GLP-1s and their potential impacts, indicating a competitive landscape in the biotech industry [1] - The company is positioned in a high-growth sector that is expected to experience exponential expansion, highlighting its potential for substantial returns through innovation [1]